NovaBridge Biosciences (NBP) Investor presentation summary

Company evolution and business model

• Transitioned from China-focused biotech to a global platform, now operating a hub-and-spoke model bridging Asian innovation to global markets.

• Focuses on asset acquisition at early clinical or IND-enabling stages, leveraging deep translational expertise and global clinical execution.

• Drives value creation by accelerating proof-of-concept and enabling attractive exits or spin-offs.

• Maintains flexibility for strategic collaborations and selective late-stage development.

• Platform supports cross-therapeutic innovation, with a strong business development capability.

Pipeline and clinical programs

• Four clinical-stage assets: Givastomig (CLDN18.2 x 4-1BB bsAb), Ragistomig (PD-L1 x 4-1BB bsAb), Uliledlimab (CD73 mAb), and VIS-101 (VEGF x Ang-2 bsAb).

• Givastomig shows robust efficacy in 1L gastric cancer, with ORR up to 77% and mPFS of 16.9 months in Phase 1b.

• VIS-101 demonstrates best-in-class potential in wet AMD, with interim Phase 2 data showing rapid, durable vision improvement.

• Ragistomig and Uliledlimab offer differentiated mechanisms and promising early clinical data in solid tumors and NSCLC, respectively.

• Multiple ongoing and planned global trials, including randomized Phase 2 for Givastomig and Phase 3 readiness for VIS-101.

Market opportunity and competitive positioning

• Addressing significant unmet needs in gastric cancer, pancreatic ductal adenocarcinoma, biliary tract carcinoma, and major ophthalmic diseases.

• Givastomig targets a $12B+ global market in gastric cancer, with broader coverage than current CLDN18.2 therapies.

• VIS-101 positioned as a next-generation agent in a multi-billion dollar anti-VEGF market, aiming for superior durability and efficacy.

• Differentiation based on broader patient eligibility, superior efficacy, and favorable safety profiles compared to existing therapies.